NCT05261113
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +17 more
- Locations
-
- University Hospital Department of Surgery Regensburg, Germany
Clinical trial condition
Carcinoma, Hepatocellular
Explore clinical trials studying Carcinoma, Hepatocellular. Study availability and eligibility vary by location and protocol.
2,099 public trials
531 recruiting studies
Carcinoma, Hepatocellular trial results
NCT05281783
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Interventional Ultrasonography Unit, Tropical Medicine Department, Beni-Suef University Hospitals Banī Suwayf, Egypt
NCT02785835
- Conditions
- Adenocarcinoma, Blood-Borne Infections, Carcinoma, +32 more
- Locations
-
- Hospital de Orihuela Orihuela, Alicante, Spain
- Hospital Clínico Universitario de San Juan Sant Joan d'Alacant, Alicante, Spain
- Hospital Marina Baixa Villajoyosa, Alicante, Spain
- Hospital German Trias i Pujol Badalona, Barcelona, Spain
NCT04008082
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
- Locations
-
- Eisai Trial Site #1 Osaka, Japan
- Eisai Trial Site #2 Tokyo, Japan
NCT02178358
- Conditions
- Adenocarcinoma, Bone Diseases, Bone Diseases, Developmental, +16 more
- Locations
-
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Beijing, China
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bengbu, China
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Changchun, China
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hangzhou, China
NCT03884751
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
- The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China
- The 81st Hospital of Chinese PLA Nanjing, Jiangsu, China
- Renji Hospital Shang Hai Jiaotong Unversity of Medicine Shanghai, Shanghai Municipality, China
NCT02178722
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +76 more
- Locations
-
- UC San Diego Moores Cancer Center La Jolla, California, United States
- The Angeles Clinic and Research Institute Los Angeles, California, United States
- US Davis Cancer Center Sacramento, California, United States
- University Of Colorado Cancer Center Aurora, Colorado, United States
NCT02224456
- Conditions
- Adenocarcinoma, Blood-Borne Infections, Carcinoma, +24 more
- Locations
-
- GSK Investigational Site Guangzhou, Guangdong, China
- GSK Investigational Site Wuhan, Hubei, China
- GSK Investigational Site Nanjing, Jiangsu, China
- GSK Investigational Site Nanjing, Jiangsu, China
NCT04722120
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
- Seoul National University Hospital Seoul, South Korea
Completed
Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma
NCT05235490
- Conditions
- Adenocarcinoma, CT Scans Prior to Surgery With a Least 2 Years of Follow-up, Carcinoma, +9 more
- Locations
-
- Paul Brousse Hospital Villejuif, France